Search
Browse By Day
Browse By Time
Browse By Person
Browse By Policy Area
Browse By Session Type
Browse By Keyword
Browse Artificial Intelligence Presentations
Program Calendar
Sign In
Search Tips
Session Submission Type: Special Event
Join us at the Presdiential Address & Awards after a full day of sessions and see the presentation of the David N. Kershaw, the Peter H. Rossi, the William Spriggs Memorial, and the Raymond Vernon Memorial Awards, and hear from the winners. Visit APPAM.org for more information about the award winners.
Afterwards, over snacks and drinks, we will hear from APPAM President Kosali Simon, Indiana University, as she delivers her Presidential Address. Afterwards, we'll have a champagne toast and dessert at the Networking Reception.
After the Breakthrough: Access, Delivery, and Who Benefits from Medical Innovation
It is hard not to be amazed by what medical science delivers: therapies that transformed HIV and hepatitis C, medications that treat opioid use disorder, GLP-1 drugs now redefine the treatment of obesity and diabetes, and disease-modifying treatments for Alzheimer's disease on the horizon. It is equally hard not to be amazed by how much else determines whether these advances improve lives. Each breakthrough poses a question that goes way beyond the discovery: does everyone who could benefit actually receive it? The evidence says no, and the gap impedes achieving population health improvements that are possible. Effective medications for opioid use disorder have existed for decades, yet most people with the condition go untreated. Who obtains a GLP-1 today depends on the insurance they hold, the state they live in, the indication on the prescription, and the channel where they buy. Programs that help family caregivers of older adults reach only some of those who could benefit. This address examines what research has learned about the distance between innovation and benefit. The frictions are human ones: how patients weigh cost, hassle, stigma, and trust; how clinicians and health systems decide what to offer and to whom; how confidence in evidence and in institutions is changing; and how much the messenger matters, including whether patients and the professionals who treat them share background and life experience. Research is well positioned to study these frictions. We have tools to do this; naturally occurring “experimental” program design reveals how delivery actually works. I end on a hopeful note. We should keep pushing for new medicines, for cancer and dementia and the chronic conditions of aging. Understanding what happens after the breakthrough is a scientific frontier of its own, and progress there raises the value of every breakthrough.